Cubist Systematic Strategies, LLC Stoke Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.65 - $10.38 $153,765 - $208,638	-20,100 Reduced 41.04%	28,876 $240,000
Q4 2022 Feb 14, 2023	BUY	$7.07 - $15.69 $242,783 - $538,794	34,340 Added 234.63%	48,976 $452,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $22.53 $340,275 - $610,382	-27,092 Reduced 64.93%	14,636 $188,000
Q2 2022 Aug 15, 2022	SELL	$10.36 - $23.93 $32,281 - $74,565	-3,116 Reduced 6.95%	41,728 $551,000
Q1 2022 May 16, 2022	BUY	$17.19 - $26.1 $569,521 - $864,719	33,131 Added 282.86%	44,844 $944,000
Q4 2021 Feb 14, 2022	SELL	$18.11 - $30.72 $5,795 - $9,830	-320 Reduced 2.66%	11,713 $281,000
Q3 2021 Nov 15, 2021	BUY	$23.65 - $34.44 $34,316 - $49,972	1,451 Added 13.71%	12,033 $306,000
Q2 2021 Aug 16, 2021	BUY	$30.53 - $41.09 $134,820 - $181,453	4,416 Added 71.62%	10,582 $356,000
Q1 2021 May 17, 2021	BUY	$36.08 - $69.81 $222,469 - $430,448	6,166 New	6,166 $239,000

125

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $386M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.